Immune cell therapy for hard-to-treat autoimmune diseases
Treatments studied
Part of Immune system & allergy clinical trials.
This study uses a patient's own immune cells, specially modified to target and reduce harmful immune cells that cause autoimmune diseases. It is for people with conditions like lupus, rheumatoid arthritis, or other listed autoimmune diseases that have not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have one of the listed autoimmune diseases (like lupus, myositis, scleroderma, pemphigus, psoriasis, rheumatoid arthritis, or vasculitis).
- Your disease must be considered moderate to severe and has not responded well to at least 12 weeks of standard therapy.
- You must have had the diagnosis for at least 6 months and be willing to use contraception as required.
- You must be able to attend regular follow-up visits and provide your medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
This trial tests a new treatment using your own immune cells, modified to target and calm the overactive immune system that causes autoimmune diseases. It may help reduce symptoms for conditions like lupus, scleroderma, and others.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.